At the recent JP Morgan Healthcare Conference, US chip giant NVIDIA (NASDAQ: NVDA) announced a new collaboration with Amgen (NASDAQ: AMGN)’s subsidiary, deCode. This partnership will see deCode leverage NVIDIA’s advanced supercomputers and the BioNeMo generative artificial intelligence (AI) platform to bolster the development of its genomic foundational models.
BioNeMo, NVIDIA’s drug discovery platform centered around generative AI, is designed to expedite the drug discovery process and represents an emerging frontier in the field. Previously, Recursion (NASDAQ: RXRX), a US-based AI firm focused on biopharma, became the first third-party to subscribe to BioNeMo, highlighting the platform’s potential. Recursion’s appeal extends to major players like Bayer and Roche, particularly in the realms of rare disease and oncology.
During the conference, Recursion and NVIDIA unveiled LOWE, Recursion’s AI drug discovery software. LOWE is a new software application based on Large Language Modeling (LLM) capable of performing intricate drug discovery tasks and managing both wet and dry lab experiments through a natural language interface. This innovation makes cutting-edge AI algorithms and computational tools accessible to users, regardless of their formal machine learning training. Furthermore, LOWE offers extensive data visualization capabilities.- Flcube.com
